Lataa...
Re-challenging immune checkpoint inhibitor in a patient with advanced non-small cell lung cancer: a case report
BACKGROUND: Currently, immune checkpoint (ICP) inhibitors are essential drugs for the treatment of non-small cell lung cancer (NSCLC). However, in patients previously treated with ICP inhibitors, the efficacy and safety of re-challenging the same or another ICP inhibitor remain unclear. CASE PRESENT...
Tallennettuna:
| Julkaisussa: | BMC Cancer |
|---|---|
| Päätekijät: | , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
BioMed Central
2018
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5859734/ https://ncbi.nlm.nih.gov/pubmed/29554874 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-018-4212-1 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|